Testing azacitidine plus NAC to treat low platelets after transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 2 study tests whether giving azacitidine plus NAC can improve a common complication after blood and marrow transplant (HSCT): persistently low platelets. It aims to see if treatment can help your blood counts recover when platelets stay very low by about day 60 or later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your platelet count is 30 or less (×10^9/L) and stays that low at day 60 after HSCT or later
- Your neutrophils (a type of infection-fighting white blood cell) have recovered well
- Your hemoglobin (a measure of red blood count) has recovered well
- Full donor chimerism has been reached (your body’s blood is now fully from the donor)
- You do not have a current cancer relapse
- You do not have an active infection or require treatment for a clot (thrombosis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
This trial tests a combination of two drugs (venetoclax and azacitidine) followed by a stem cell transplant from a donor for patients with a specific type of acute myeloid leukemia (AML) that has low bone marrow cell count or has developed from a prior blood disorder. The goal is to control the disease and give you a chance at a cure through transplantation.
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
This trial tests whether taking a medication called N-acetylcysteine (NAC) before a half-matched stem cell transplant can help your body make new platelets faster. Platelets are blood cells that help prevent bleeding, which is a common problem after transplant for severe aplastic anemia.
Hear when a new Stem Cell Transplant Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.